

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zhaoke Ophthalmology Limited

兆科眼科有限公司

(Incorporated in the British Virgin Islands with limited liability and continued in the Cayman Islands)

(Stock Code: 6622)

**VOLUNTARY ANNOUNCEMENT –
NMPA ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION
FOR TAB014 FOR THE TREATMENT OF wAMD**

This announcement is made by the board of directors (the “**Board**”) of Zhaoke Ophthalmology Limited (the “**Company**”) on a voluntary basis.

The Board of the Company is pleased to announce that the National Medical Products Administration (“**NMPA**”) of China has recently accepted the Biologics License Application (“**BLA**”) for one of the Company’s core products, TAB014, for the treatment of wet age-related macular degeneration (“**wAMD**”). It is the first bevacizumab-based antibody filing BLA indicated for wAMD in China.

The BLA is based on the successful results of the Company’s Phase III clinical trial in China. It is a randomized, double-blind and non-inferiority study. The main objective of the study is to evaluate the change from baseline in best corrected visual acuity (BCVA) at week 52 in the TAB014-treated subjects group compared with Lucentis®-treated subjects group. The study involved approximately 57 centres and enrolled a total of 488 patients, led by Professor Chen Youxin from Peking Union Medical College Hospital as the Principal Investigator.

In January 2025, the Company announced the positive top-line results from the Phase III clinical trial of TAB014. The clinical trial successfully met its primary endpoints and key secondary endpoints.

ABOUT TAB014

TAB014 (recombinant humanized anti-vascular endothelial growth factor (“**VEGF**”) monoclonal antibody) is an ophthalmic formulation of bevacizumab being developed for the treatment of wAMD. The main pathological feature of wAMD is choroidal angiogenesis in the macula, with VEGF playing an important role in the angiogenesis process. TAB014 is able to bind specifically to VEGF and block it from binding to its receptors, thereby inhibiting angiogenesis. TAB014 will eventually be administered as an intravitreal injection for the treatment of wAMD.

ABOUT wAMD

wAMD is a leading cause of vision loss and blindness in people over 50 years old in China and globally. According to China Insights Consultancy the market size of wAMD drugs in China is forecast to increase from US\$241.5 million to approximately US\$3.5 billion from 2019 to 2030, at a CAGR of 27.5%. TAB014 is the first bevacizumab-based antibody under clinical development indicated for wAMD in China, and is expected to be a cost-effective therapy. The clinical research and commercialization project in relation to TAB014 was listed by the Development Center for Medical Science & Technology of the National Health Commission of China as a special major project for technologies of innovative manufacturing of major new drugs at the end of 2019.

ABOUT THE AGREEMENT WITH TOT BIOPHARM CO., LTD.

In March 2022, the Company announced that Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited (“**Zhaoke Guangzhou**”), a wholly-owned subsidiary of the Company and TOT BIOPHARM Co., Ltd. (“**TOT Suzhou**”, a wholly-owned subsidiary of TOT BIOPHARM International Company Limited (“**TOT BIOPHARM**”), SEHK: 1875), entered into a supplemental agreement (the “**Current Supplemental Agreement**”), pursuant to which Zhaoke Guangzhou will have full control in the execution of clinical trials and the ultimate decision-making power in the development and commercialization of TAB014 in China, Hong Kong and Macau. Zhaoke Guangzhou is also given the right of developing TAB014 for other ophthalmic indications besides wAMD or novel formulations for ophthalmic indications. TOT Suzhou will continue to be responsible for the manufacturing of TAB014 for clinical trial and commercial purposes.

Cautionary statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately commercialize TAB014 successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Zhaoke Ophthalmology Limited
Dr. Li Xiaoyi
Chairman

Hong Kong, June 12, 2025

As at the date of this announcement, the Board comprises Dr. Li Xiaoyi and Mr. Dai Xiangrong as executive Directors; Ms. Leelalertsuphakun Wanee and Ms. Tiantian Zhang as non-executive Directors; and Mr. Wong Hin Wing, Prof. Lo Yuk Lam and Mr. Liew Fui Kiang as independent non-executive Directors.